Fetching results...
0 items found

A1199: Clinical fracture incidence in metastatic hormone-sensitive prostate cancer and risk-reduction following addition of zoledronic acid to androgen deprivation therapy with or without docetaxel: Long-term results from the STAMPEDE trial

Mr. C. (Craig) Jones
Jones C.1, Sachdeva A.1, Murphy L.2, Murray M.2, Brown L.2, Brown J.3, Mc Closkey E.3, Attard G.4, Parmar M.2, James N.5, Sydes M.R.2, Clarke N.1
1Christie and Salford Royal NHS Hospitals, Dept. of Urology, Manchester, United Kingdom, 2University College London, Medical Research Council Clinical Trials Unit, London, United Kingdom, 3University of Sheffield, Dept. of Oncology and Metabolism, Sheffield, United Kingdom, 4University College London, Cancer Institute, London, United Kingdom, 5Institute of Cancer Research, Prostate And Bladder Cancer Research, London, United Kingdom
38th Annual EAU Congress
Date – Time - Location
13 March 2023, 14:15 - 15:45, Pink Area, Coral 4
Abstract Session 62 - Novel prognostic factors and optimal treatment for patients with metastatic prostate cancer
Prostate Cancer, metastatic - Complications
  • © 2023 European Association of Urology
  • Disclaimer